Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16029438 | 1.00 | PIK3CA (0.41) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R2 | |
| SCHEMBL1485071 | 0.84 | MAP3K14 (0.42) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R1 | |
| SCHEMBL17613233 | 0.81 | MAP3K14 (0.42) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R1 | |
| SCHEMBL19594749 | 0.80 | PIK3CA (0.42) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R1 | |
| SCHEMBL12689314 | 0.80 | MAP3K14 (0.43) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R1 | |
| SCHEMBL16074590 | 0.78 | PIK3CA (0.38) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R2 | |
| SCHEMBL1484978 | 0.78 | MAP3K14 (0.43) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R1 | |
| SCHEMBL1485015 | 0.77 | MAP3K14 (0.44) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R1 | |
| SCHEMBL12696762 | 0.77 | PIK3CA (0.41) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R2 | |
| SCHEMBL1485289 | 0.77 | MAP3K14 (0.40) | PIK3CAPIK3CGPIK3CDMAP3K14PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3404032-A2 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2970329-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014140073-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | PIK3C2B, PIP4K2C, PIK3C2A | PIK3CA 9/4885PIK3CG 11/4885PIK3CD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.